KSK Diagnostics GmbH, a Hamburg, Germany-based developer of molecular point-of-care tests, closed a Series A financing round of undisclosed amount.
Backers included Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds.
The company intends to use the funds for the development of molecular point-of-care diagnostic tests and subsequent market launch.
Co-founded by Dr. Stefan Kulick, Dr. Peter Scheinert and Dr. Guido Krupp, KSK Diagnostics uses isothermal amplification technology to develop molecular point-of-care diagnostic tests for patient-oriented diagnostics, which enable the doctor to make a diagnosis after 30 minutes and coordinate the treatment. In addition to the diagnosis of pathogens, the company’s tests are suited to quickly clarify issues related to tumour diagnostics.